Corroborating this observation is the fact that tumor-intrinsic RB activation resulted in no overt changes to Pdcd1 or Ctla4 and even a potential reduction in PD-L1, which would suggest that approaches designed around those targets would prove inconsequential. The gene discussed is PDCD1; the disease is neoplasm.